Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 50 of 391

    1.

    Genetic engineering of IgG-glucuronidase fusion proteins.

    Boado RJ, Pardridge WM.

    J Drug Target. 2009 Oct 14. [Epub ahead of print]PMID: 19827970 [PubMed - as supplied by publisher]Related articles

    2.

    IgG-single chain Fv fusion protein therapeutic for alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey.

    Boado RJ, Lu JZ, Hui EK, Pardridge WM.

    Biotechnol Bioeng. 2009 Oct 8. [Epub ahead of print]PMID: 19816967 [PubMed - as supplied by publisher]Related articles

    3.

    Alzheimer's disease drug development and the problem of the blood-brain barrier.

    Pardridge WM.

    Alzheimers Dement. 2009 Sep;5(5):427-32.PMID: 19751922 [PubMed - indexed for MEDLINE]Related articles

    4.

    Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey.

    Boado RJ, Pardridge WM.

    Drug Metab Dispos. 2009 Dec;37(12):2299-304. Epub 2009 Sep 9.PMID: 19741036 [PubMed - in process]Related articlesFree article

    5.

    AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys.

    Boado RJ, Hui EK, Lu JZ, Pardridge WM.

    J Biotechnol. 2009 Oct 26;144(2):135-41. Epub 2009 Sep 6.PMID: 19735678 [PubMed - in process]Related articles

    6.

    Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier.

    Hui EK, Boado RJ, Pardridge WM.

    Mol Pharm. 2009 Sep-Oct;6(5):1536-43.PMID: 19624167 [PubMed - in process]Related articles

    7.

    Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery.

    Pardridge WM, Boado RJ.

    Pharm Res. 2009 Oct;26(10):2227-36. Epub 2009 Jul 17.PMID: 19609743 [PubMed - in process]Related articlesFree article

    8.

    IgG-paraoxonase-1 fusion protein for targeted drug delivery across the human blood-brain barrier.

    Boado RJ, Zhang Y, Zhang Y, Wang Y, Pardridge WM.

    Mol Pharm. 2008 Nov-Dec;5(6):1037-43.PMID: 19434854 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Near complete rescue of experimental Parkinson's disease with intravenous, non-viral GDNF gene therapy.

    Zhang Y, Pardridge WM.

    Pharm Res. 2009 May;26(5):1059-63. Epub 2008 Dec 23.PMID: 19104914 [PubMed - indexed for MEDLINE]Related articles

    10.

    Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology.

    Xia CF, Boado RJ, Pardridge WM.

    Mol Pharm. 2009 May-Jun;6(3):747-51.PMID: 19093871 [PubMed - indexed for MEDLINE]Related articles

    11.

    Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse.

    Boado RJ, Zhang Y, Wang Y, Pardridge WM.

    Biotechnol Bioeng. 2009 Mar 1;102(4):1251-8.PMID: 18942151 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses.

    Pardridge WM.

    Bioconjug Chem. 2008 Jul;19(7):1327-38. Epub 2008 Jun 12. Review.PMID: 18547095 [PubMed - indexed for MEDLINE]Related articles

    13.

    Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans.

    Boado RJ, Zhang Y, Zhang Y, Xia CF, Wang Y, Pardridge WM.

    Bioconjug Chem. 2008 Mar;19(3):731-9. Epub 2008 Feb 16.PMID: 18278853 [PubMed - indexed for MEDLINE]Related articles

    14.

    Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter.

    Xia CF, Boado RJ, Zhang Y, Chu C, Pardridge WM.

    J Gene Med. 2008 Mar;10(3):306-15.PMID: 18085726 [PubMed - indexed for MEDLINE]Related articles

    15.

    GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier.

    Boado RJ, Zhang Y, Zhang Y, Wang Y, Pardridge WM.

    Biotechnol Bioeng. 2008 Jun 1;100(2):387-96.PMID: 18080333 [PubMed - indexed for MEDLINE]Related articles

    16.

    Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology.

    Xia CF, Zhang Y, Zhang Y, Boado RJ, Pardridge WM.

    Pharm Res. 2007 Dec;24(12):2309-16. Epub 2007 Oct 11.PMID: 17926121 [PubMed - indexed for MEDLINE]Related articles

    17.

    Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier.

    Boado RJ, Zhang Y, Zhang Y, Xia CF, Wang Y, Pardridge WM.

    Biotechnol Bioeng. 2008 Feb 1;99(2):475-84.PMID: 17680664 [PubMed - indexed for MEDLINE]Related articles

    18.

    Blood-brain barrier genomics and cloning of a novel organic anion transporter.

    Chu C, Li JY, Boado RJ, Pardridge WM.

    J Cereb Blood Flow Metab. 2008 Feb;28(2):291-301. Epub 2007 Aug 1.PMID: 17667996 [PubMed - indexed for MEDLINE]Related articles

    19.

    Brain drug development and brain drug targeting.

    Pardridge WM.

    Pharm Res. 2007 Sep;24(9):1729-32. Epub 2007 Jul 13. No abstract available. PMID: 17629776 [PubMed - indexed for MEDLINE]Related articles

    20.

    Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer.

    Zhang Y, Wang Y, Boado RJ, Pardridge WM.

    Pharm Res. 2008 Feb;25(2):400-6. Epub 2007 Jun 30.PMID: 17602284 [PubMed - indexed for MEDLINE]Related articles

    21.

    Drug targeting to the brain.

    Pardridge WM.

    Pharm Res. 2007 Sep;24(9):1733-44. Epub 2007 Jun 7. Review.PMID: 17554607 [PubMed - indexed for MEDLINE]Related articles

    22.

    Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses.

    Pardridge WM.

    J Control Release. 2007 Oct 8;122(3):345-8. Epub 2007 Apr 6.PMID: 17512078 [PubMed - indexed for MEDLINE]Related articlesFree article

    23.

    Comparison of cDNA and genomic forms of tyrosine hydroxylase gene therapy of the brain with Trojan horse liposomes.

    Xia CF, Chu C, Li J, Wang Y, Zhang Y, Boado RJ, Pardridge WM.

    J Gene Med. 2007 Jul;9(7):605-12.PMID: 17471587 [PubMed - indexed for MEDLINE]Related articles

    24.

    shRNA and siRNA delivery to the brain.

    Pardridge WM.

    Adv Drug Deliv Rev. 2007 Mar 30;59(2-3):141-52. Epub 2007 Mar 16. Review.PMID: 17434235 [PubMed - indexed for MEDLINE]Related articles

    25.

    Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation.

    Boado RJ, Zhang Y, Zhang Y, Xia CF, Pardridge WM.

    Bioconjug Chem. 2007 Mar-Apr;18(2):447-55. Epub 2007 Feb 22.PMID: 17315944 [PubMed - indexed for MEDLINE]Related articlesFree article

    26.

    Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier.

    Boado RJ, Zhang Y, Zhang Y, Pardridge WM.

    Biotechnol Bioeng. 2007 Aug 15;97(6):1376-86.PMID: 17286273 [PubMed - indexed for MEDLINE]Related articles

    27.

    Blood-brain barrier genomics.

    Pardridge WM.

    Stroke. 2007 Feb;38(2 Suppl):686-90. Review.PMID: 17261716 [PubMed - indexed for MEDLINE]Related articlesFree article

    28.

    Molecular trojan horses for blood-brain barrier drug delivery.

    Pardridge WM.

    Discov Med. 2006 Aug;6(34):139-43.PMID: 17234133 [PubMed - in process]Related articles

    29.

    Blood-brain barrier delivery.

    Pardridge WM.

    Drug Discov Today. 2007 Jan;12(1-2):54-61. Epub 2006 Nov 13. Review.PMID: 17198973 [PubMed - indexed for MEDLINE]Related articles

    30.

    Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier.

    Boado RJ, Zhang Y, Zhang Y, Pardridge WM.

    Biotechnol Bioeng. 2007 Feb 1;96(2):381-91.PMID: 16937408 [PubMed - indexed for MEDLINE]Related articles

    31.

    Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion.

    Zhang Y, Pardridge WM.

    Brain Res. 2006 Sep 21;1111(1):227-9. Epub 2006 Aug 1.PMID: 16884698 [PubMed - indexed for MEDLINE]Related articles

    32.

    Molecular Trojan horses for blood-brain barrier drug delivery.

    Pardridge WM.

    Curr Opin Pharmacol. 2006 Oct;6(5):494-500. Epub 2006 Jul 12. Review.PMID: 16839816 [PubMed - indexed for MEDLINE]Related articles

    33.

    Decline in exogenous gene expression in primate brain following intravenous administration is due to plasmid degradation.

    Chu C, Zhang Y, Boado RJ, Pardridge WM.

    Pharm Res. 2006 Jul;23(7):1586-90. Epub 2006 Jun 21.PMID: 16779704 [PubMed - indexed for MEDLINE]Related articles

    34.

    Site-directed mutagenesis of cysteine residues of large neutral amino acid transporter LAT1.

    Boado RJ, Li JY, Chu C, Ogoshi F, Wise P, Pardridge WM.

    Biochim Biophys Acta. 2005 Sep 15;1715(2):104-10.PMID: 16125134 [PubMed - indexed for MEDLINE]Related articles

    35.

    Molecular biology of the blood-brain barrier.

    Pardridge WM.

    Mol Biotechnol. 2005 May;30(1):57-70. Review.PMID: 15805577 [PubMed - indexed for MEDLINE]Related articles

    36.

    Imaging gene expression in regional brain ischemia in vivo with a targeted [111in]-antisense radiopharmaceutical.

    Suzuki T, Zhang Y, Zhang YF, Schlachetzki F, Pardridge WM.

    Mol Imaging. 2004 Oct;3(4):356-63.PMID: 15802053 [PubMed - indexed for MEDLINE]Related articles

    37.

    Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor.

    Zhang Y, Pardridge WM.

    J Pharmacol Exp Ther. 2005 Jun;313(3):1075-81. Epub 2005 Feb 17.PMID: 15718287 [PubMed - indexed for MEDLINE]Related articlesFree article

    38.

    Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy.

    Pardridge WM.

    NeuroRx. 2005 Jan;2(1):129-38. Review.PMID: 15717064 [PubMed - indexed for MEDLINE]Related articlesFree article

    39.

    The blood-brain barrier: bottleneck in brain drug development.

    Pardridge WM.

    NeuroRx. 2005 Jan;2(1):3-14. Review.PMID: 15717053 [PubMed - indexed for MEDLINE]Related articlesFree article

    40.

    The blood-brain barrier and neurotherapeutics.

    Pardridge WM.

    NeuroRx. 2005 Jan;2(1):1-2. No abstract available. PMID: 15717052 [PubMed - indexed for MEDLINE]Related articlesFree article

    41.

    Human LAT1 single nucleotide polymorphism N230K does not alter phenylalanine transport.

    Boado RJ, Li JY, Wise P, Pardridge WM.

    Mol Genet Metab. 2004 Dec;83(4):306-11.PMID: 15589117 [PubMed - indexed for MEDLINE]Related articles

    42.

    Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology.

    Suzuki T, Wu D, Schlachetzki F, Li JY, Boado RJ, Pardridge WM.

    J Nucl Med. 2004 Oct;45(10):1766-75.PMID: 15471847 [PubMed - indexed for MEDLINE]Related articlesFree article

    43.

    Organ-specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice.

    Zhu C, Zhang Y, Zhang YF, Yi Li J, Boado RJ, Pardridge WM.

    J Gene Med. 2004 Aug;6(8):906-12.PMID: 15293349 [PubMed - indexed for MEDLINE]Related articles

    44.

    Intravenous, non-viral RNAi gene therapy of brain cancer.

    Pardridge WM.

    Expert Opin Biol Ther. 2004 Jul;4(7):1103-13. Review.PMID: 15268677 [PubMed - indexed for MEDLINE]Related articles

    45.

    Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer.

    Zhang Y, Zhang YF, Bryant J, Charles A, Boado RJ, Pardridge WM.

    Clin Cancer Res. 2004 Jun 1;10(11):3667-77.PMID: 15173073 [PubMed - indexed for MEDLINE]Related articlesFree article

    46.

    Gene therapy of the brain: the trans-vascular approach.

    Schlachetzki F, Zhang Y, Boado RJ, Pardridge WM.

    Neurology. 2004 Apr 27;62(8):1275-81. Review.PMID: 15111662 [PubMed - indexed for MEDLINE]Related articles

    47.

    Log(BB), PS products and in silico models of drug brain penetration.

    Pardridge WM.

    Drug Discov Today. 2004 May 1;9(9):392-3. No abstract available. PMID: 15081955 [PubMed - indexed for MEDLINE]Related articles

    48.

    Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter.

    Zhang Y, Schlachetzki F, Zhang YF, Boado RJ, Pardridge WM.

    Hum Gene Ther. 2004 Apr;15(4):339-50.PMID: 15053859 [PubMed - indexed for MEDLINE]Related articles

    49.

    Holy grails and in vitro blood-brain barrier models.

    Pardridge WM.

    Drug Discov Today. 2004 Mar 15;9(6):258. No abstract available. PMID: 15003241 [PubMed - indexed for MEDLINE]Related articles

    50.

    Blood-brain barrier drug targeting: the future of brain drug development.

    Pardridge WM.

    Mol Interv. 2003 Mar;3(2):90-105, 51. Review.PMID: 14993430 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Find related data

    Search details

    » See more...